Trial Profile
Experimental fMRI Study on the Comparison of the Brain Function Effects of a Single Dose of Guanfacine and Lisdexamfetamine Relative to Placebo in Children and Adolescents With ADHD.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2022
Price :
$35
*
At a glance
- Drugs Guanfacine (Primary) ; Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Acronyms AGUALIS
- 16 Aug 2022 Planned End Date changed from 31 Dec 2022 to 31 Mar 2025.
- 16 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 17 Feb 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2022.